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ABSTRACT
Objective: The objective of the study to analyze osteocalcin levels in induction and alternate phase, associated with clinical manifestation.
Methods: We conducted a prospective longitudinal study. This study was subject to approval by the Ethics Committee of Dr. Soetomo Teaching 
Hospital Surabaya. Osteocalcin levels were measured before and after induction phases and 4 weeks after the alternate phase. Samples were collected 
in the morning at 08.00-09.00 am.
Results: A total of 15 patients were included in this study. The suppression of osteocalcin levels in the induction phase was 53.33%. After the alternate 
phase, osteocalcin levels increased 175.82%. Clinical manifestation as bone pain/cramps only appeared 33% in the induction phase and 20% in 
the alternate phase. The mean suppression of osteocalcin levels in the group with induction phase duration therapy ≥28 days and without calcium 
supplementation was higher than 21-27 days and with calcium supplementation. Osteocalcin levels increased in the alternate phase also in patients 
with and without calcium supplementation. The result of analysis showed there was no significant difference among all groups (p>0.05).
Conclusion: Suppression of osteocalcin levels was reversible after the alternate phase. It shows that tapering off regimen is important. Clinical sign 
as pain bone/cramps almost showed no manifest in all of these patients.
Keywords: Osteocalcin, Nephrotic syndrome, Prednisone, Corticosteroid, High dose prednisone, Long-term prednisone, Bone formation, Bone 
marker, Pediatric.
INTRODUCTION
Nephrotic syndrome (NS) is a glomerular disease with massive 
proteinuria >40 mg/m2/h or >50 mg/kg/d or urinary protein creatinine 
ratio >2 mg/mg. Other clinical manifestations are hypoalbuminemia 
(≤2.5 g/dl) and edema [1-3]. Based on the report, NS incident occurrence 
of children <14 year of age in Indonesia is 6/100.000 [2]. NS patients 
are treated with high dose and long-term prednisone therapy which 
may decrease the function of osteoblasts and lead to suppression of 
bone formation [4,5]. A meta-analysis of over 80 studies in adults found 
that use of ≥5 mg/d of prednisolone (or equivalent) was associated with 
significant reductions in bone mineral density (BMD) and an increase 
in fracture risk within 3-6 months of treatment initiation [6]. Based on 
systematic review and meta-analysis in children ≤18 years taking long-
term systemic glucocorticoid therapy, the prevalence of fracture was 
29-45% [7]. Based on those meta-analysis, NS patients are at risk of 
losing bone mass which leads to osteopenia, osteoporosis, and fracture. 
Therefore, bone metabolism in NS patients need to be evaluated.
Biochemical marker such as osteocalcin may be useful in monitoring 
bone metabolism. Osteocalcin is a noncollagenous protein in mature 
human bone. It is a small protein of 49 amino acids including three 
residues of gamma-carboxyglutamic acid and its synthesis is essentially 
specific to osteoblasts [8,9]. Osteocalcin is a sensitive marker to 
glucocorticoids because it directly affects the expression of osteocalcin 
at the transcriptional level by binding to the glucocorticoid receptors 
(GR) and leading to repression of osteocalcin gene up to 40% of basal 
levels [10,11]. Osteocalcin levels of children with NS in Indonesia have 
not been established. Besides that, osteocalcin levels after 4 weeks the 
alternate phase in NS patients have not been evaluated. Therefore, this 
study is proposed to analyze osteocalcin levels in the induction phase 
and 4 weeks of the alternate phase which associated with clinical 
manifestation.
METHODS
We conducted a prospective longitudinal study from May to October 
2016. This study protocol was subject to approval by the Ethics 
Committee of Dr. Soetomo Teaching Hospital Surabaya. We included 
children aged <18 years who were diagnosed with an initial attack NS, 
infrequent relapses NS, frequently relapsing NS, and steroid dependent 
NS. The parents of the patients signed informed consents for this study. 
The patients with NS steroid resistant were excluded from this study.
NS patients were treated with 60 mg/m2/d prednisone or 2 mg/kg/d 
(maximum 60 mg/d) for ±4 weeks (induction phase), followed by 
40 mg/m2/d or 1.5 mg/kg/d (maximum 40 mg/d) on alternate 
days for ±4 weeks (alternate phase). Samples were collected at 
08.00-09.00 am from the patients before they started treatment, after 
the induction phase, and after alternate phase. All patients had normal 
renal function (glomerular filtration rate >90 ml/minutes/1.73 m2).
Osteocalcin levels were measured accordance with Enzyme-Linked 
Immunosorbent Assay method. Medical history and clinical data were 
collected from patient information and based on the medical record.
Nominal data were presented as frequency distribution, and interval 
data were described as mean and standard deviation. Collected data 
were analyzed using Statistical Package for the Social Science 20,0. 
Distribution data were checked with One-Sample Kolmogorov-Smirnov 
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test. Differences in osteocalcin levels between phase were checked 
with Paired t-test and General Linear Model Repeated Measures. 
Independent t-test and One-Way ANOVA were used to compare 
differences in osteocalcin levels among groups. For all test, a probability, 
p<0.05 was examined significant.
RESULTS
A total of 15 patients (9 boys and 6 girls) were enrolled from Pediatric 
Department Nephrology Division of Dr. Soetomo Teaching Hospital 
Surabaya. The patients were in the active phase of NS, with either their 
first attack (n=4) or during a relapse (n=11). Their ages ranged from 
2 to 15 years with most of the weight were ≤20.9 kg. Before induction 
phase, 27% of patient had osteocalcin level in the normal range, 47% up 
in the normal range, and 27% below the normal range. The majority of 
the patients had normal of calcium and phosphorus levels, also did not 
experience bone pains/cramps. Table 1 shows baseline characteristics 
of examined children and history of the duration and cumulative dose 
of prednisone for 1 year before induction (t=0).
Osteocalcin levels of patients before treatment started (t=0), after 
induction phase (t=1), and after alternate phase (t=2) were shown in 
Table 2. Almost all patients had osteocalcin levels at t=0 higher than 
the normal range, except four patients (AM, KY, AP, and RA) whose 
osteocalcin levels were lower than normal range. Other than KY, 
osteocalcin levels at t=2 were higher than the normal range. Three 
patients (MA infrequent relapses NS, AP frequently relapsing NS, RA-
dependent steroid NS) had osteocalcin profile different from other 
patients, which osteocalcin levels at t=0 lower than t=1. Osteocalcin 
suppression of DA in the induction phase was as low as 2.44% compared 
Table 1: Baseline characteristics of patients
Patient characteristics Total patient (n=15) Mean±SD
Number of patients n (%)
Gender
Boys 9 (60) -
Girls 6 (40) -
Age (year)
<2 0 (0) -
2-< 4 (27) 3.5±1.3
6-< 8 (53) 7.5±1.6
12-18 3 (20) 14±1.0
Weight (kg)
≤20.9 8 (53) 16.4±3.13
21-40.9 5 (33) 26.9±8.05
41-60 2 (14) 48.5±2.12
Diagnosis
Initial attack nephrotic syndrome 4 (27) -
Infrequent relapses nephrotic syndrome 3 (20) -
Frequently relapsing nephrotic syndrome 2 (13) -
Steroid dependent nephrotic syndrome 6 (40) -
Osteocalcin level before induction (µg/l)
<45 4 (27) 19.151±15.358
45-105 4 (27) 70.923±22.976
>105 7 (46) 134.623±11.526
Cumulative dose of prednisone 1 year before induction (g)
Not taking prednisone 5 (33) -
<5 6 (40) 3.1±1.39
5-10 4 (37) 5.9±5.2
>10 0 (0) -
Duration of prednisone 1 year before induction (days)
Not taking prednisone 5 (33) -
1-225 9 (60) 168.2±53.96
226-450 1 (7) 229
>450 0 (0) -
Cumulative dose of calcium supplement 1 year before induction (g)
Not taking calcium supplement 6 (40) -
<293 2 (13) 175.3±148.14
293-586 7 (47) 327.6±17.29
Calcium level before induction
No measurement 2 (13) -
Normal (2.2-2.7 mmol/l) 13 (87) 2.3±0.13
Abnormal (<2.2 or>2.7 mmol/l) 0 (0) -
Phosporus level before induction
No measurement 7 (47) -
Normal (0.87-2.1 mmol/l) 8 (53) 1.6±0.21
Abnormal (<0.87 or>2.1 mmol/l) 0 (0) -
Edema
No edema 1 (7) -
Palpebra 4 (26) -
Extremitas 1 (7) -
Anasarca 9 (60) -
Bone pain/cramps
Yes 5 (33) -
No 10 (67) -
SD: Standard deviation
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to high percentage of other patients. There was no significant difference 
in osteocalcin level of initial attack, infrequent relapses, frequently 
relapsing, and dependent steroid NS at t=0, t=1, t=2 (p=0.847; p=0.572; 
p=0.889, respectively).
The mean osteocalcin level of 15 patients was presented in Table 2 
showed that after the induction phase, osteocalcin levels decrease 
53.33% (86.844±52.380 to 40.531±36.030 µg/l) and after alternate 
phase increase 175.82% (40.531±36.030 to 111.792±45.268 µg/l). 
There was a significant difference between osteocalcin levels after 
induction phase versus (vs.) before treatment and after alternate phase 
versus induction phase (p=0.007 and p=0.000, respectively).
Data in Table 3 that showed the mean suppression of osteocalcin 
levels in group with induction phase duration therapy ≥28 days 
and without calcium supplementation was higher than 
21-27 days and with calcium supplementation (−56.752±58.674 
and −64.467±67.921 vs. −25.434±51.932 and −30.376±43.166) µg/l, 
respectively. Osteocalcin levels increased in the alternate phase also 
in patients with and without calcium supplementation. The result of 
analysis showed that there was no significant difference among all 
groups (p>0.05).
Clinical manifestation as bone pain/cramps only appeared 33% in the 
induction phase and 20% in the alternate phase showed in Table 4.
DISCUSSION
Osteocalcin levels of 7 out of 15 patients at t=0 was higher than the 
normal range. As shown in Table 2 indicate that children in growth 
period associated with increased activity of osteoblast [8]. Normal 
range is osteocalcin levels in Caucasian children. The difference of 
these ethnic may be caused difference of BMD. Based on the report, the 
prevalence of vitamin D deficiency in people who live in high-latitude 
regions, such as Caucasian children was higher than people in tropical 
regions like Indonesian children [12]. Deficiency of vitamin D will be 
Table 2: Osteocalcin levels of patients
Patients code Osteocalcin levels (µg/l)
Normal range t=0 t=1 t=2
Initial attack nephrotic syndrome
AM
(G/3 y/11.8 kg)
44-93 37.892 16.931 63.635
DI
(G/8 y/20 kg)
50-89 137.321 34.434 141.462
KY
(B/2 y/12.3 kg)
64-70 24.274 2.458 34.818
AI
(B/14 y/47 kg)









Infrequent relapses nephrotic syndrome
JA
(G/7 y/18 kg)
53-97 138.218 39.088 124.855
SR
(G/7 y/21.8 kg)
53-97 128.356 10.740 63.806
MA
(B/7 y/20.2 kg)













51-84 114.762 51.700 141.023
AP
(B/11 y/50 kg)









Steroid dependent nephrotic syndrome
RF
(B/15 y/29.7 kg)
61-105 103.339 32.342 132.283
ND
(B/4 y/16 kg)
53-90 63.166 40.753 128.825
RA
(B/6 y/17 kg)
51-84 11.978 21.029 56.164
DA
(G/5 y/21 kg)
66-88 129.361 126.208 142.190
NH
(G/8 y/22 kg)
50-89 67.776 45.235 136.766
FH
(B/13 y/39.8 kg)









Mean±SD (15 patients) 86.844±52.3804* 40.531±36.0304*5* 111.792±45.2685*
% - ↓53.33 ↑175.82
Range 2.458-147.632 2.458-126.208 34.818-180.370
1*p=0.847, 2*p=0.572, 3*p=0.889, 4*p=0.007 (t=0 vs. t=1), 5*p=0.000 (t=1 vs. t=2), G: Girl, B: Boy, SD: Standard deviation, y: Years
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Table 3: Osteocalcin change based on duration therapy and consume of calcium supplementation
Group Number of patients Mean±SD of osteocalcin change (µg/l) Significancy (p)
Induction phase 21-27 days 5 −25.434±51.932 0.332
Induction phase≥28 days 10 −56.752±58.674
Alternate phase≤14 days 6 83.682±23.654 0.325
Alternate phase>14 days 9 62.980±45.191
With calcium supplement (induction phase) 8 −30.376±43.166 0.261
Without calcium supplement (induction phase) 7 −64.467±67.921
With calcium supplement (alternate phase) 10 58.547±30.793 0.067
Without calcium supplement (alternate phase) 5 96.688±42.694
SD: Standard deviation
Table 4: Clinical manifestation
Patient code Bone pain/cramp
t=0 t=1 t=2
Initial attack nephrotic 
syndrome
AM No No No
DI No No No
KY No No No
AI No Yes No
Infrequent relapses 
nephrotic syndrome
JA Yes No Yes 
SR No No No
MA Yes Yes No
Frequently relapsing 
nephrotic syndrome
AR No Yes No
AP Yes No No
Steroid dependen 
nephrotic syndrome
RF No No No
ND No Yes No
RA Yes No Yes 
DA Yes No No
NH No No No
FH No Yes Yes
Total (%) Yes=5 (33) Yes=5 (33) Yes=3 (20)
No=10 (67) No=10 (67) No=12 (80)
reduced transcription of osteocalcin; therefore, osteocalcin level in 
most patients was higher than normal range [13]. Difference of ethnic 
also might cause genetic variation, polymorphisms in the promoter 
gene of osteocalcin (rs1800247), vitamin D receptor gene, and 
regulatory region of the type 1 collagen gene, COLIA1, also mutation 
of low-density lipoprotein receptor-related protein 5 (LRP5) therefore 
may cause difference osteocalcin levels [14-16]. Four patients (AM, KY, 
AP, and RA) whose osteocalcin levels lower than normal range may be 
caused by low quality of BMD in these patients.
Three patients (MA infrequent relapses NS, AP frequently relapsing NS, 
RA-dependent steroid NS) had osteocalcin profile different from other 
patients, whose osteocalcin levels at t=0 was lower than t=1 which 
caused by a history of high-dose and long-term prednisone since 2015, 
2013, and 2011, respectively. The suppression osteocalcin of DA in the 
induction phase as low as 2.44% because this patient had high protein 
intake. Protein intake affects bone in several ways, such as providing 
the structural matrix of bone, optimizing insulin-like growth factor-1 
levels, and reported increasing intestinal calcium absorption [17].
Osteocalcin levels of initial attack, infrequent relapses, frequently 
relapsing, and dependent steroid NS at t=0, t=1, t=2 were not 
significantly different because patients were given the same dose. 
Kano et al. [18] reported osteocalcin levels of children with steroid-
responsive NS 4 weeks after starting prednisolone therapy (induction 
phase) decreased 68.54%. The other study that was reported by 
Mohamed and Abdul-Latif [19], osteocalcin levels decreased 30.59% 
after 1 month of therapy in the initial attack NS. The decreasing of 
osteocalcin levels after induction phase also occurred in 15 patients 
in this study. Osteocalcin levels of 15 patients decrease 53.33% 
(86.844±52.380 - 40.531±36.030 µg/l). It showed a decreasing function 
of osteoblast which leads to osteopenia, osteoporosis, and increasing risk 
of fracture. This suppression was caused by prednisone induce nuclear 
factors of the CCAAT enhancer binding protein family and the induction 
of peroxisome proliferator-activated receptor γ 2, both of which play 
essential roles in adipogenesis. An additional mechanism by which 
prednisone inhibit osteoblast cell differentiation is by opposing Wnt/β-
catenin signaling. Prednisone has pro-apoptotic effects on osteoblasts 
and osteocytes due to activation of caspase 3, a common downstream 
effector of several apoptotic signaling pathways [4,5]. Besides that, 
prednisone has directly affected the expression of osteocalcin at the 
transcriptional level by binding to the GR and subsequently to specific 
recognition sequences in the proximal promoter leading to a repression 
of osteocalcin gene [10].
Kano et al. [18] observed osteocalcin levels 8 weeks after the alternate 
phase and showed increasing from 6.7±2.6 µg/l to 15.0±6.4 µg/l. As 
mentioned previously that study of osteocalcin levels after 4 weeks 
the alternate phase in NS patients have not been evaluated. Therefore, 
our study evaluated it and the result showed increasing 175.82% 
(40.531±36.030 - 111.792±45.268 µg/l). This increasing indicates that the 
suppression of osteocalcin is reversible while tapering dose of prednisone.
The mean suppression of osteocalcin levels in the group with induction 
phase duration therapy ≥28 days was higher than 21-27 days. This 
condition as reported Godschalk and Downs [20] and Biyikli et al. [21] 
that the suppression of osteocalcin is dose dependent, which the higher 
dose of prednisone, the higher suppression of osteocalcin levels. Patients 
without calcium supplement had osteocalcin levels more suppressed 
than with calcium supplement. This result shows that patients without 
calcium supplement are at risk of hypocalcemia, thus stimulates 
parathyroid hormone (PTH). PTH acts on osteoclast by increasing 
receptor activator of NF-κB ligand release, leading to promotion of 
osteoclastogenesis and reduce osteoblastogenesis, therefore suppress 
transcription of osteocalcin [22]. It shows that calcium supplement 
should be given to prevent hypocalcemia in NS patient.
Variation on increasing of osteocalcin levels in the alternate phase is 
affected by BMD each patient and intake patients. Dietary such as milk, 
fish, egg, and green leaves (spinach, broccoli) is intake high calcium, 
protein, vitamin D, and vitamin K which may increase transcription of 
osteocalcin [23,24].
CONCLUSION
Suppression of osteocalcin levels was reversible after alternate phase. 
It shows that tapering off regimen is important. Clinical sign as pain 
bone/cramps almost showed no manifest in all of these patients.
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